

Appl. No. 09/727,198
After Final Amendment dated June 25, 2003
Reply to Final Office Action of March 11, 2003

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- Be noted*
1. (previously amended) A factor for treating patients afflicted with a disease that leads to an immunosuppressed state in the patient, which consists essentially of:
therapeutic fractions greater than 50 kDa, of a supernatant derived from lymphocyte cells, which have been subjected to mitogenic stimulation in serum free medium.
 2. (original) The factor of claim 1, wherein said lymphocyte cells are lymph node lymphocyte cells.
 3. (original) The factor of claim 1, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.
 4. (original) The factor of claim 3, wherein said mitogenic stimulation includes the presence of IL2 and soluble anti-CD3 monoclonal antibody followed by re-stimulation in the presence of insoluble anti-CD3 monoclonal antibody.
 5. (original) The factor of claim 1, wherein said lymphocyte cells are peripheral blood lymphocyte cells.
 6. (original) The factor of claim 1 wherein said factor comprises an approximately 70-80 kDa fraction of said 50 kDa fraction.
 7. (original) The factor of claim 4, which comprises an approximately 70-80 kDa fraction thereof.

Appln. No. 09/727,198
After Final Amendment dated June 25, 2003
Reply to Final Office Action of March 11, 2003

8. (original) The factor of claim 4, wherein said lymphocyte cells are derived from one or more of a cancer patient, an HIV patient, or a patient free of cancer and HIV.

Claims 9-56 (canceled)

57. (currently amended) A factor for treating a patient afflicted with a disease that leads to an immunosuppressed state in the patient, wherein said factor ~~comprises~~ consists essentially of a protein whose active form has a molecular weight greater than 50 kDa, said protein being derived from lymphocyte cells which have been subjected to mitogenic stimulation.
58. (original) The factor of claim 57, wherein said lymphocyte cells are lymph node lymphocyte cells.
59. (original) The factor of claim 57, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.
60. (original) The factor of claim 59, wherein said mitogenic stimulation includes the presence of IL2 and soluble anti-CD3 monoclonal antibody followed by re-stimulation in the presence of insoluble anti-CD3 monoclonal antibody.
61. (original) The factor of claim 57, wherein said lymphocyte cells are peripheral blood lymphocyte cells.
62. (original) The factor of claim 57 wherein the active form of said protein has a molecular weight of approximately 70- 80 kDa.
63. (original) The factor of claim 60 wherein the active form of said protein has a molecular weight of approximately 70- 80 kDa.
64. (original) The factor of claim 57, wherein said lymphocyte cells are derived from one or more of a cancer patient, an HIV patient, or a patient free of cancer and HIV.

Appln. No. 09/727,198
After Final Amendment dated June 25, 2003
Reply to Final Office Action of March 11, 2003

65. (original) The factor of claim 57, wherein the active form of said protein is a multimer.
66. (original) The factor of claim 60, wherein the active form of said protein is a multimer.

Becon'd.